← Eichor
Condition: Advanced Or Metastatic Non Small Cell Lung Cancer Nsclc Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Advanced Or Metastatic Non Small Cell Lung Cancer Nsclc

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subje
Phase 2 · 1 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT07175220Study of XB010 in Subjects With Solid Tumors
Phase 1 · 20 location(s) · Exelixis · NCT06545331A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Phase 1 · 34 location(s) · Incyte Corporation · NCT06179160A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
Phase 1/Phase 2 · 25 location(s) · Merck Sharp & Dohme LLC · NCT07286149A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination Wi
Phase 2/Phase 3 · 1 location(s) · Shanghai Henlius Biotech · NCT07459751A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations
Phase 1 · 1 location(s) · National Cancer Center, China · NCT06362980To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Lo
Phase 2 · 7 location(s) · OBI Pharma, Inc · NCT05442060Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Phase 3 · 604 location(s) · National Cancer Institute (NCI) · NCT04181060A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.
Phase 3 · 1 location(s) · Sinocelltech Ltd. · NCT07362459Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
Phase 1 · 1 location(s) · Dwight Owen · NCT06616623First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Phase 1 · 10 location(s) · Plexium, Inc. · NCT07284186A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
Phase 1/Phase 2 · 103 location(s) · AstraZeneca · NCT06996782Pembrolizumab for Advanced NSCLC and PS 2-3
Phase 2 · 1 location(s) · Icahn School of Medicine at Mount Sinai · NCT05589818Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in P
Phase 2 · 8 location(s) · CrystalGenomics, Inc. · NCT05841472A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Phase 1/Phase 2 · 26 location(s) · Frontier Medicines Corporation · NCT06244771Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM
Phase 2 · 1 location(s) · Brown University · NCT06974604Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)
Phase 2/Phase 3 · 11 location(s) · Swiss Cancer Institute · NCT07149649A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carbop
Phase 3 · 260 location(s) · Hoffmann-La Roche · NCT06793215Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Mon
Phase 3 · 36 location(s) · ImmunityBio, Inc. · NCT06745908DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)
Phase 1/Phase 2 · 1 location(s) · Dizal Pharmaceuticals · NCT07070440JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study
Phase 2 · 2 location(s) · Shanghai Junshi Bioscience Co., Ltd. · NCT07518160A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Phase 1/Phase 2 · 1 location(s) · Blueprint Medicines Corporation · NCT07629960Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07641023Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic H
Phase 1 · 91 location(s) · AstraZeneca · NCT04686305Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
Phase 1 · 8 location(s) · Olema Pharmaceuticals, Inc. · NCT06784193Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
Phase 2 · 26 location(s) · Teligene US · NCT05168566A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)
Phase 3 · 1 location(s) · Beijing Pearl Biotechnology Limited Liability Company · NCT05989542A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participan
Phase 3 · 351 location(s) · Mirati Therapeutics Inc. · NCT06875310A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
Phase 2 · 83 location(s) · AstraZeneca · NCT07098338ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer
Phase 2 · 2 location(s) · iLeukon Therapeutics, Inc. · NCT07452224
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.